Simultaneous disruption of estrogen receptor and Wnt/β-catenin signaling is involved in methyl amooranin-mediated chemoprevention of mammary gland carcinogenesis in rats

Molecular and Cellular Biochemistry

Volumn 384, Issue 1-2, 2013, Pages 239-250

  Mandal, Animesh ^a   Bhatia, Deepak ^a   Bishayee, Anupam ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b American University of Health Sciences   (United States)

Author keywords

Catenin; Cyclin D1; DMBA; Estrogen receptors; Mammary carcinogenesis; Oleanane triterpenoid

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; BETA CATENIN; CYCLIN D1; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; METHYL AMOORANIN; TRITERPENOID; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; CANCER CELL; CELL NUCLEUS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; IMMUNOHISTOCHEMISTRY; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BETA CATENIN; CARCINOGENESIS; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; KIDNEY; LIVER; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; TRITERPENES; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84889062695     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1803-7     Document Type: Article

References (68)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-33
3. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270-282
4. Tsai MJ, O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486
5. Matthews J, Gustafsson JA (2003) Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3:281-292
6. Williams GP (2010) The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. Eur J Cancer Prev 19:256-271
7. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguère V (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol 11:353-365
8. Ali S, Coombs RC (2000) Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 5:271-281
9. Saji S, Jensen EV, Nilsson S, Rylander T, Warner M, Gustafsson JA (2000) Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci USA 97:337-342
10. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13:1558-1568
11. Brennan KR, Brown AMC (2004) Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 9:119-131
12. Incassati A, Chandramouli A, Eelkema R, Cowin P (2010) Key signaling nodes in mammary gland development and cancer: β-catenin. Breast Cancer Res 12:213
13. Clevers H (2006) Wnt/β-catenin signaling in development and disease. Cell 127:469-480
14. Bishayee A (2013) β-Catenin: a novel biomarker and therapeutic target in liver cancer. In: Georgakilas A (ed) Cancer biomarkers. CRC Press, Boca Raton, pp 51-75
15. Ozaki S, Ikeda S, Ishizaki Y, Kurihara T, Tokumoto N, Iseki M, Arihiro K, Kataoka T, Okajima M, Asahara T (2005) Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep 14:1437-1443
16. Clifford RL, Deacon K, Knox AJ (2008) Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor β1: requirement for Smads, β-catenin, and GSK3β. J Biol Chem 283:35337-35353
17. Prosperi JR, Goss KH (2010) A Wnt-ow of opportunity: targeting the Wnt/β-catenin pathway in breast cancer. Curr Drug Target 11:1074-1088
18. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC (2000) β-Catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97:4262-4266
19. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176:2911-2920
20. López-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, Sutherland RL, O'Toole SA (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 19:301-309
21. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP (2001) Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 3:793-801
22. Prasad CP, Gupta SD, Rath G (2007) Ralhan R (2007) Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression. Oncology 73:112-117
23. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, Keramopoulos A, Davaris PS, Pignatelli M (2001) Expression patterns of beta-catenin in in situ and invasive breast cancer. Eur J Surg Oncol 27:31-36
24. Khalil S, Tan GA, Giri DD, Zhou XK, Howe LR (2012) Activation status of Wnt/β-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS One 7:e33421
25. Rabi T, Bishayee A (2009) Terpenoids and breast cancer chemoprevention. Breast Cancer Res Treat 115:223-239
26. Bishayee A, Ahmed S, Brankov N, Perloff M (2011) Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci 16:980-996
27. Yang H, Dou QP (2010) Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer. Curr Drug Targets 11:733-744
28. Miller JA, Thompson PA, Hakim IA, Sherry Chow H, Thomson CA (2011) d-Limonene: a bioactive food component from citrus and evidence for a potential role in breast cancer prevention and treatment. Oncol Rev 5:31-42
29. Rabi T, Karunagaram D, Nair MK, Bhattathiri VN (2002) Cytotoxic activity of amooranin and its derivatives. Phytother Res 16:S84-S86
30. Rabi T, Ramachandran C, Fonseca HB, Nair RP, Alamo A, Melnick SJ, Escalon E (2003) Novel drug amooranin induces apoptosis through caspase activity in human breast carcinoma cell lines. Breast Cancer Res Treat 80:321-330
31. Rabi T, Wang L, Banerjee S (2007) Novel triterpenoid 25-hydroxy-3- oxoolean-12-en-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Breast Cancer Res Treat 101:27-36
32. Rabi T (1996) Antitumor activity of amooranin from Amoora rohituka stem bark. Curr Sci 70:80-81
33. Rabi T, Banerjee S (2008) Novel synthetic triterpenoid methyl 25-hydroxy-3-oxoolean-12-en-28-oate induces apoptosis through JNK and p38 MAPK pathways in human breast adenocarcinoma MCF-7 cells. Mol Carcinog 47:415-423
34. Rabi T, Huwiler A, Zangemeister-Wittke U (2013) AMR-Me inhibits PI3 K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells. Mol Carcinog (in press)
35. Bishayee A, Mandal A, Thoppil RJ, Darvesh AS, Bhatia D (2013) Chemopreventive effect of a novel oleanane triterpenoid in a chemically induced rodent model of breast cancer. Int J Cancer 133:1054-1064
36. Malejka-Giganti D, Niehans GA, Reichert MA, Bliss RL (2000) Post-initiation treatment of rats with indole-3-carbinol or beta-naphthoflavone does not suppress 7,12-dimethylbenz[a]anthracene-induced mammary gland carcinogenesis. Cancer Lett 160:209-218
37. Costa I, Solanas M, Escrich E (2002) Histopathological characterization of mammary neoplastic lesions induced with 7,12-dimethylbenz(a)anthracene in the rat: a comparative analysis with human breast tumors. Arch Pathol Lab Med 126:915-927
38. Mandal A, Bhatia D, Bishayee A (2013) Suppression of inflammatory cascade is implicated in methyl amooranin-mediated inhibition of experimental mammary carcinogenesis. Mol Carcinog (in press)
39. Russo J, Russo IH (1996) Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 39:7-20
40. Kilańczyk E, Gwoździński K, Wilczek E, Filipek A (2012) Up-regulation of CacyBP/SIP during rat breast cancer development. Breast Cancer (in press)
41. Ponzone R, Biglia N, Jacomuzzi ME, Mariani L, Dominguez A, Sismondi P (2006) Antihormones in prevention and treatment of breast cancer. Ann NY Acad Sci 1089:143-158
42. Henderson BE, Feigelson HS (2000) Hormonal carcinogenesis. Carcinogenesis 21:427-433
43. Korach KS, Couse JF, Curtis SW, Washburn TF, Lindzey J, Kimbro KS, Eddy EM, Migliaccio S, Snedeker SM, Lubahn DB, Schomberg DW, Smith EP (1996) Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog Horm Res 51:159-186
44. Leygue E, Dotzlaw H, Watson PH, Murphy LC (1998) Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis. Cancer Res 58:3197-3201
45. Lazennce G, Bresson D, Lucas A, Chauveau C, Vignon F (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142:4120-4130
46. Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7:46-53
47. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H (2011) Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12:496-503
48. Cazzaniga M, Bonanni B (2012) Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol 2012:985620
49. Harvey JM, Clark GM, Osborne K, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481
50. Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537-2541
51. Foster JS, Henley DC, Ahamed S, Wimalasena J (2001) Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 12:320-327
52. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME (1997) Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17:5338-5347
53. Caldon CE, Sutherland RL, Musgrove E (2010) Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle 9:1918-1928
54. Roy PG, Thompson AM (2006) Cyclin D1 and breast cancer. Breast 15:718-727
55. Yang C, Trent S, Ionescu-Tiba V, Lan L, Shioda T, Sgroi D, Schmidt EV (2006) Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res 66:11649-11658
56. Jang TJ, Kang MS, Kim H, Kim DH, Lee JI, Kim JR (2000) Increased expression of cyclin D1, cyclin E and p21(Cip1) associated with decreased expression of p27(Kip1) in chemically induced rat mammary carcinogenesis. Jpn J Cancer Res 91:1222-1232
57. Kuramoto T, Morimura K, Yamashita S, Okochi E, Watanabe N, Ohta T, Ohki M, Fukushima S, Sugimura T, Ushijima T (2002) Etiology-specific gene expression profiles in rat mammary carcinomas. Cancer Res 62:3592-3597
58. Shan L, He M, Yu M, Qiu C, Lee NH, Liu ET, Snyderwine EG (2002) cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a] anthracene. Carcinogenesis 23:1561-1568
59. Rani R, Kansal VK, Kaushal D, De S (2011) Dietary intervention of cow ghee and soybean oil on expression of cell cycle and apoptosis related genes in normal and carcinogen treated rat mammary gland. Mol Biol Rep 38:3299-3307
60. Papaconstantinou AD, Shanmugam I, Shan L, Schroeder IS, Qiu C, Yu M, Snyderwine EG (2006) Gene expression profiling in the mammary gland of rats treated with 7,12-dimethylbenz[a]anthracene. Int J Cancer 118:17-24
61. Chatterjee M, Das S, Janarthan M, Ramachandran HK, Chatterjee M (2011) Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis in rats. Eur J Pharmacol 668:99-106
62. Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, Ying H, Dominguez I, Sonenshein GE, Cardiff RD, Xiao ZX, Sherr DH, Seldin DC (2005) Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol 33:726-737
63. Li H, Pamukcu R, Thompson WJ (2002) β-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther 1:621-625
64. Thangapazham RL, Passi N, Maheshwari RK (2007) Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol Ther 6:1938-1943
65. Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R (2009) Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/β-catenin signaling. Chem Biol Interact 181:263-271
66. Murillo G, Peng X, Torres KE, Mehta RG (2009) Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev Res 2:942-950
67. Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, Piazza GA (2011) Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res 4:1275-1284
68. Wang Y, Ding L, Wang X, Zhang J, Han W, Feng L, Sun J, Jin H, Wang XJ (2012) Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. Am J Transl Res 4:44-51